Clinical Trials Logo

Conjunctivitis, Allergic clinical trials

View clinical trials related to Conjunctivitis, Allergic.

Filter by:

NCT ID: NCT00985296 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)

ABC CAC
Start date: September 2009
Phase: N/A
Study type: Observational

To evaluate the effect of Conjunctival Allergen Challenge (CAC) with Dust Mites on nasal and ocular allergic symptoms following allergen exposure in the Allergen BioCube (ABC).

NCT ID: NCT00985075 Completed - Clinical trials for Allergic Rhinoconjunctivitis

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

Start date: December 2008
Phase: N/A
Study type: Observational

The objective of this study is to evaluate ocular and nasal signs and symptoms in patients with seasonal allergic rhinoconjunctivitis following allergen exposure in the Allergen BioCube.

NCT ID: NCT00982163 Completed - Clinical trials for Allergic Conjunctivitis

A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

Start date: August 2008
Phase: N/A
Study type: Observational

The study was designed to evaluate the pattern of seasonal allergic signs and symptoms consistent with ongoing ocular allergic inflammation during ragweed season. It was hypothesized that a pattern of ongoing ocular allergic inflammation existed in certain subjects.

NCT ID: NCT00973453 Completed - Allergic Rhinitis Clinical Trials

Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The aim of the study is to establish the maximum tolerated dose of PURETHAL Mites that is achieved by 90% of the patients with less than 20% of the injections giving rise to a swelling of > 5 cm and the optimal regimen to reach this maximum dose will be determined.

NCT ID: NCT00955825 Completed - Clinical trials for Grass Pollen-related Allergic Rhinoconjunctivitis

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.

NCT ID: NCT00917488 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended

NCT ID: NCT00916760 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerized with glutaraldehyde) of the subcutaneous injection of Parietaria Judaica pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the score regarding symptoms and consumption of the medication.

NCT ID: NCT00891436 Completed - Clinical trials for Allergic Conjunctivitis to Tree Pollen or Grass Pollen

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Start date: April 2009
Phase: Phase 4
Study type: Interventional

Rationale and objectives: Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when used for the treatment of seasonal allergic rhinitis during the ragweed pollen season. Although this is the only published report of an intranasal corticosteroid shown to effectively treat ocular symptoms, the mechanism has not been delineated. Furthermore, the tears of patients with allergic conjunctivitis are known to have increased concentrations of cytokines and allergic mediators. The objective of this study is to determine if the positive effects of Veramyst nasal spray on ocular symptoms is via the inhibition of allergic mediators in the eyes. The investigators will conduct a double blind placebo controlled trial to determine if Veramyst nasal spray decreases the amount of allergic mediators in the tears of subjects randomized to Veramyst nasal spray versus placebo. The investigators will also compare the subjects' symptoms to the amount of allergic mediators detected in their tears.

NCT ID: NCT00889330 Completed - Clinical trials for Allergic Conjunctivitis

Safety and Efficacy Study of a Eye Drop for Eye Allergy

Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.

NCT ID: NCT00889252 Completed - Clinical trials for Allergic Conjunctivitis

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers.